Company

Bracco Diagnostics


AHA: Higher MACE rates, costs associated with certain contrast agents

Conference News | Monday, May 24 2010
Major adverse coronary events (MACE) are a complication in cardiac caths and PCI with substantial resource utilization and costs, according to a study presented at American Heart Association’s Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Scientific Sessions in Washington, D.C., last week.
 

JIC: Ionic contrast media leads to fewer thrombus formations

Clinical Studies | Wednesday, March 24 2010
Experimental, animal and human studies have shown that the use of ionic contrast media compared with nonionic agents during PCI leads to fewer episodes of thrombus formation, according to two reviews in the March supplement of the Journal of Invasive Cardiology.
 

FDA finds Bracco’s imaging agent is misbranded

Industry News | Tuesday, January 26 2010
The FDA's Division of Drug Marketing, Advertising and Communications has informed Bracco Diagnostics that its Web site for IsoVue (iopamidol injection) misbrands the drug by omitting and minimizing the risks associated with the agent and contains false and unsubstantiated claims.
 

Bracco teams with Datalliance for vendor managed inventory program

Partnerships & Alliances | Thursday, January 21 2010
Bracco Diagnostics has selected Datalliance VMI as the platform for its vendor managed inventory program.
 

MR technique delivers superior pelvic visualization

Portal Exclusives | Thursday, November 05 2009
Time-resolved MR angiography (TR-MRA) is a useful sequence for the assessment of ovarian vein reflux, which may aid the evaluation of pelvic congestion syndrome, according to research published this month in the American Journal of Roentgenology.
 

RSNA: Bracco/Acist Medical updates EmpowerCTA contrast injector

Conference News | Wednesday, October 28 2009
Bracco Diagnostics and Acist Medical Systems (Booth #2829) are featuring the updated EmpowerCTA contrast injector, with the integrated IRiSCT data management system for diagnostic imaging in radiology at the 2009 Radiological Society of North America (RNSA).
 

AHJ: No difference between GE’s Vispaque and Bracco's IsoVue for adverse events

Clinical Studies | Wednesday, October 28 2009
There is no significant difference between iodixanol (Visipaque, GE Healthcare) and iopamidol (IsoVue, Bracco Diagnostics) in either peak increase in serum creatinine or risk of contrast-induced nephropathy, according to a prospective, multicenter, randomized, double-blind trial in the November issue of the American Heart Journal.
 

Reformations deliver diagnostic CT data

Portal Exclusives | Thursday, September 03 2009
Volumetric oblique coronal reformations are a useful noninvasive method to provide diagnostic information about periampullary abnormalities as well as show secondary features important for local staging and management of the ampulla of Vater, according to research published this month in the American Journal of Roentgenology.
 

Ultrasound growth driven by hand-carried devices

Industry News | Saturday, August 01 2009
The world medical ultrasound equipment, accessories, and maintenance services market is expected to reach $4.7 billion by 2012, according to market research firm Marketstrat.
 

JACC: Risk of kidney injury equivalent between iso- and low-osmolar contrast media

Clinical Studies | Wednesday, July 29 2009
Past studies have indicated a benefit regarding the use of an iso-osmolar contrast agent versus low-osmolar contrast media. A new meta-analysis in the July issue of JACC: Cardiovascular Interventions suggests the two types of contrast agents are equivalent in terms of the risk of acute kidney injury.
 

Bracco wins $11.4M from GE for false advertising claims

Top Stories | Monday, March 30 2009
The U.S. District Court in Trenton, N.J. has ruled that GE Healthcare and its predecessor companies, including Amersham, engaged in a false and misleading advertising with a promotional campaign claiming that its x-ray contrast agent Visipaque was superior to Bracco's x-ray contrast agent Isovue.
 

Bracco showcases expanded portfolio

In Review | Tuesday, December 23 2008
Bracco Imaging unveiled its expanded product portfolio at the 2008 RSNA, including contrast media and delivery systems for CT/cardiology, MRI, nuclear medicine and virtual colonoscopy (VC).
 

Bracco Diagnostics

Previews | Wednesday, October 29 2008
Bracco Diagnostics (Booth 2845), along with ACIST Medical Systems, is showcasing a portfolio of  imaging agents and delivery systems, such as MultiHance, which is indicated for intravenous use in MRI of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.
 
Web Exclusives

Feature: U.S. needs national strategy to curb imaging overutilization

Medical imaging overutilization--a growing concern in the U.S.--exposes patients to unnecessary radiation, while also adding to rising healthcare costs, according to a study published online Aug. 24 in Radiology. In an interview, William R. Hendee, PhD, lead author, reviewed various methods by which medical imaging could be curtailed.

Radiology: Prelim study shows CE breast CT outperforms CT, mammo

Dedicated contrast-enhanced (CE) breast CT delivered significantly improved conspicuity of malignant breast lesions, including ductal carcinoma in situ (DCIS), compared with unenhanced breast CT and mammography, according to a study published in the September issue of Radiology.

Radiology: Rad role may evolve as image-guided biopsies trend up

CT, ultrasound and MRI have helped shift biopsy techniques away from more invasive approaches toward image-guided percutaneous techniques, according to a study published in the September issue of Radiology. The trend toward less-invasive approaches translates into enhanced safety and efficiency and could lead to more interaction between patients and radiologists.

CMS Webinar: Incentive payments to offset EHR adoption, not reimburse

The Centers for Medicare & Medicaid Services’ (CMS) EHR incentive payments are not considered reimbursement for money expended on EHR technology, but are intended to offset the cost associated with adoption and ongoing meaningful use, according to CMS during an Aug. 12 webinar.

CMS webinar: Eligible professionals can expect EHR incentives in 2011

Funding incentives for EHR use is the main goal of the Centers for Medicare & Medicaid Services' (CMS) meaningful use initiative, and there are incentive programs for both hospitals and eligible professionals, according to Elizabeth Holland, health insurance specialist at the Department of Health and Human Services, who spoke during a CMS-sponsored webinar Aug. 8.

Webinar: Stage 1 of meaningful use is for quality reporting acclimation

Stage 1 requirements for meaningful use incentives aim to strike a balance between the overall goal of EHR use and widespread adoption, while avoiding added work, said Jonathan Teich, MD, PhD, chief medical informatics officer at Elsevier Health Services, during a HIMSS webinar titled “Meaningful Use: Safety and Quality of Care.”

PORTALS

Advanced Visualization

Molecular Imaging

Integration Tools & Interoperability

More Portal Topics